Michael Hayden

Michael Hayden News

  • Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’

    Teva Pharmaceutical Industries Ltd., which just two years ago was analysts’ highest-rated stock among the world’s 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.

  • China’s Cyberspies Outwit Model for Bond’s Q

    Among defense contractors, QinetiQ North America is known for spy-world connections and an eye- popping product line. Its contributions to national security include secret satellites, drones, and software used by U.S. special forces in Afghanistan and the Middle East.

  • Lawmakers Fault U.S. Agencies for Lapses in Boston

    A trip to Russia by Tamerlan Tsarnaev, one of two brothers accused in the Boston Marathon bombings, may have escaped scrutiny because U.S. agencies didn’t share information, lawmakers said yesterday.

  • Lawmakers Fault U.S. Agencies for Lapses in Boston

    A trip to Russia by Tamerlan Tsarnaev, one of two brothers accused in the Boston Marathon bombings, escaped notice because U.S. agencies failed to share information, members of Congress said yesterday

  • Limits Seen in White House Cybersecurity Executive Order

    The White House may have difficulty bolstering U.S. cyber defenses through an executive order unless there’s enough public support, according to former National Security Agency director Michael Hayden.

  • Ex-CIA Director Hayden on U.S. Cyber Security

    Sept. 30 (Bloomberg) -- Former CIA Director Michael Hayden talks about cyber security issues facing the U.S., Marion Blakey, president of the Aerospace Industries Association, discusses the need to avoid automatic cuts to U.S. defense spending. Bloomberg Government's Nela Richardson and Cady North report on financial regulation and the Volcker Rule. They speak with Peter Cook on Bloomberg Government's "Capitol Gains," which airs on Bloomberg Television. (Source: Bloomberg)

  • Teva to Test MS Pill Laquinimod in Combination Therapy

    Teva Pharmaceutical Industries Ltd. will test its experimental multiple-sclerosis pill in combination therapies as the company mounts a response to oral competitors to its best-selling injection Copaxone.

  • Teva Focuses on Central Nervous System, Respiratory Drugs

    Teva Pharmaceutical Industries Ltd. will focus drug-development efforts under new Chief Executive Officer Jeremy Levin on respiratory and central nervous system illnesses as the company seeks to replace medicines set to lose patent protection in the next three years.

  • Teva Ends Collaboration on CureTech’s Cancer Medicine

    Teva Pharmaceutical Industries Ltd. ended an alliance with an Israeli biotechnology company for the development of an experimental cancer drug as Chief Executive Officer Jeremy Levin narrows the company’s research focus.

  • Hayden Sees Limitation in Cybersecurity Exec. Order

    Former National Security Agency director Michael Hayden discusses public support for U.S. cyber defenses

Advertisement
Sponsored Links
Advertisement
Curation software by Lingospot